LIFE Grows AmpliSeq Portfolio - Analyst Blog
April 03 2013 - 11:48AM
Zacks
Global biotechnology tools company – Life Technologies
Corp (LIFE) continued the expansion of its Ion AmpliSeq
portfolio with the recent launch of two Ion AmpliSeq Community
Panel designs for BRCA1, BRCA2 and Colon and Lung Cancer
Panels.
The company expects this new set of Ion AmpliSeq technology to
help researchers study samples by delivering more rapid and
comprehensive sequencing of Gene Mutations. Life Technologies plans
to speak on the use of Ion AmpliSeq panels in clinical research at
the American Association of Cancer Research (AACR) on Saturday, Apr
6.
According to the company, the Ion AmpliSeq BRCA panel helps
develop a simple high-throughput workflow with efficiency in least
time. The company claimed that, with this solution, it has detected
all the expected mutations of the 65 samples tested to date. Life
Technologies proclaimed that this AmpliSeq technology helps
comprehensive sequencing of difficult mutations,
including long homopolymers, in BRCA1 and BRCA2
genes.
On the other hand, the Ion AmpliSeq Colon and Lung Cancer panel
design helps describe a cancer according to the molecular
sub-population that composes the lesion, which is impossible with
traditional methods.
In Oct 2011, Life Technologies launched the Ion AmpliSeq Cancer
Panel to help scientists sequence dozens of genes in cancer
research samples using a simple workflow. In Mar 2012, the company
expanded its AmpliSeq offerings with the launch of Ion AmpliSeq
Custom Panels as well as with the accessibility of the Ion AmpliSeq
Designer. Last June, the company launched its Comprehensive Cancer
and Inherited Disease Panels.
The Ion franchise was inducted into Life Technologies’ portfolio
with the acquisition of Ion Torrent, a DNA sequencing company, in
Oct 2010. For the past few quarters, the company has been recording
robust growth from its Ion personal genome machine (“PGM”) that was
launched in Dec 2010, thereby taking the total number of system
placements to 700 in 2011.
The Ion franchise was inducted into Life Technologies’ portfolio
with the acquisition of Ion Torrent, a DNA sequencing company, in
Oct 2010. For the past few quarters, the company has been recording
robust revenue growth on the back of this Ion Torrent
technology.
Last year, new product introduction in this field more than
doubled the revenue of Ion Torrent franchise for the second
consecutive time. In Feb 2013, a dozen of new products for the Ion
Torrent platform were launched based on advancing clinical research
across the world. These new products enabled Ion Torrent
semiconductor sequencing technology to expand 1,000-folds in just 2
years and gain a 60% market share of benchtop sequencers.
The company is satisfied with the progress made so far with Ion
Torrent technologies and expects the growth momentum to continue.
This growth was also supported by more PGM placements and the
launch of Ion Proton system in Sep 2012, in line with the prior
expectations.
The company now carries a Zacks Rank #3 (Hold). However, other
stocks in the medical device sector, carrying a Zacks Rank #1
(Strong Buy), such as Medical Action Industries
Inc. (MDCI), Given Imaging (GIVN) and
Cyberonics Inc. (CYBX) appear impressive.
CYBERONICS INC (CYBX): Free Stock Analysis Report
GIVEN IMAGING (GIVN): Free Stock Analysis Report
LIFE TECHNOLOGS (LIFE): Free Stock Analysis Report
MEDICAL ACTION (MDCI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Jul 2024 to Aug 2024
Given Imaging (NASDAQ:GIVN)
Historical Stock Chart
From Aug 2023 to Aug 2024